Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,379 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diabetes Diagnosis Clear all
Completed Phase 2 Interventional

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
Interventions
PB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 14, 2026, 7:14 PM EDT
Recruiting Not applicable Interventional

The GRoceries Aimed at Increasing Nutrition Study

NCT07167004
View directory record Official record
Conditions
Type 2 Diabetes, Type II Diabetes Mellitus, Type II Diabetes, Pre-diabetes, Pre-diabetic, Pre-diabetic State, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes Mellitus, Type 2 Diabetes (T2DM)
Interventions
Marketing Nudges Only, Marketing Nudges + Dynamically Adapted Financial Incentives
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 14, 2026, 7:14 PM EDT
Completed No phase listed Observational

Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.

NCT01809093
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus
Interventions
Blood draw
Biological
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Minutes and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 14, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Common Genetic Variation and Type 2 Diabetes

NCT00707616
View directory record Official record
Conditions
Pre-diabetes
Interventions
Oral glucose tolerance test
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 14, 2026, 7:14 PM EDT
Recruiting Phase 3 Interventional

Improving Mobility After Revascularization in Peripheral Artery Disease

NCT06686121
View directory record Official record
Conditions
Peripheral Artery Disease, Intermittent Claudication, Peripheral Vascular Disease, Mobility Limitation, Revascularization
Interventions
Home Based Exercise, Nitrate Rich Beetroot Juice, Attention Control, Placebo Beetroot Juice Without Nitrate
Behavioral · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Tucson, Arizona • Downey, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 7:14 PM EDT
Active, not recruiting No phase listed Observational

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

NCT03945747
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
Interventions
Blood draw, Urine sample collection, DXA scan
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 14, 2026, 7:14 PM EDT
Enrolling by invitation Not applicable Interventional

Virtual Lifestyle Intervention for Weight Management and Cardiovascular Heal

NCT07572721
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Multicomponent Virtual Lifestyle Intervention
Behavioral
Lead sponsor
Truemedicine Inc
Other
Eligibility
30 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 14, 2026, 7:14 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

NCT01255163
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

NCT01852214
View directory record Official record
Conditions
Diabetes Mellitus, Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 14, 2026, 7:14 PM EDT
Terminated Phase 2 Interventional Results available

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

NCT00529204
View directory record Official record
Conditions
Diabetes Complications, Fatty Liver
Interventions
exenatide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 14, 2026, 7:14 PM EDT
Completed No phase listed Observational

Immune Response in Hypersensitivity Pneumonitis

NCT03873649
View directory record Official record
Conditions
Hypersensitivity Pneumonitis
Interventions
Bronchoscopy with lavage
Other
Lead sponsor
Nabeel Hamzeh
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

NCT00501592
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Fatty Liver
Interventions
INT-747, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lowering Caloric Density of the Diet

NCT02674971
View directory record Official record
Conditions
Obesity, Feeding Behavior
Interventions
Common components of intervention
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

NCT00859898
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 14, 2026, 7:14 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

NCT01752985
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
BMS-813160, Placebo matching with BMS-813160
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

NCT00323414
View directory record Official record
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

NCT05669599
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions
Maridebart Cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

NCT00995930
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 14, 2026, 7:14 PM EDT
Completed No phase listed Observational Results available

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

NCT05465317
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
62,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 7:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Daily Blood Glucose Trends in Patients at Risk for Diabetes

NCT06000735
View directory record Official record
Conditions
Stress, Blood Sugar; High, Cholesterol, Elevated, Diet Habit
Interventions
7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2
Device
Lead sponsor
Karol E. Watson, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Is MyPlate Approach to Helping Overweight Patients Lose Weight More Patient-centered?

NCT02514889
View directory record Official record
Conditions
Obesity
Interventions
Calorie-counting, MyPlate
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Long Beach, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Phase 4 Interventional

A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care

NCT00939250
View directory record Official record
Conditions
Type 2 Diabetes, Major Depressive Disorder
Interventions
Diabetes and depression intervention, Diabetes intervention
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 14, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplementation on Cardiovascular Risk Factors

NCT01412710
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cholecalciferol
Drug
Lead sponsor
Florida International University
Other
Eligibility
30 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 14, 2026, 7:14 PM EDT
Not yet recruiting Not applicable Interventional

ENLIGHT Trial: ESG With Fundal Mucosal Ablation

NCT07792226
View directory record Official record
Conditions
Obesity, Obesity (Body Mass Index >30 kg/m2)
Interventions
Endoscopic Sleeve Gastroplasty (ESG), Fundal Mucosal Ablation
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 14, 2026, 7:14 PM EDT